Navigation Links
Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
Date:12/7/2007

a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which is in a Phase 1 clinical trial in advanced cancer patients; RDEA806 for gout, which is expected to enter a Phase 2 efficacy trial in the first half of 2008. Ardea also is developing a next-generation NNRTI and a next-generation MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of having active development programs with four new chemical entities (NCEs) in the clinic for three distinct indications by the end of 2007, with an additional one-to-two indications in inflammatory diseases in the first half of 2008, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... synthetic processes prefer to settle into equilibriuma state ... within the realm of non-equilibrium conditions where new ... energy and phases, such as temperature fluctuations, freezing ... to regulate their body temperature, airplanes to fly, ... , But even though these conditions exist ...
(Date:7/24/2014)... July 24, 2014 Your cell ... in modeling lithium-ion battery storage capacity. , New ... a theoretical model created at Lawrence Livermore ... that predicts how carbon components will perform as ... emphasizes the urgent need for higher-performance batteries. Several ...
(Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
(Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... valuable source of biofuel. Researchers writing in BioMed Central,s ... shown that the juice of reject watermelons can be ... a team of researchers at the USDA-Agricultural Research Service,s ... to evaluate the biofuel potential of juice from ,cull, ...
... , , NEW YORK, ... filed suit yesterday against Celgene Corporation (Nasdaq: CELG ... "unjust enrichment" regarding the Company,s sale of thalidomide (THALOMID(R) and ... alleges that Ms. Jacobson developed the original and novel idea ...
... , , SAN ... ), a biopharmaceutical company focused on developing and commercializing novel pain ... its Board of Directors as a director and Audit Committee chairman, ... CEO of Keren Pharmaceutical, a company focused on exploiting a novel, ...
Cached Biology Technology:NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5
(Date:7/24/2014)... wildlife loss leads to conflict among people around the ... Society (WCS) Health & Ecosystems: Analysis of Linkages (HEAL) ... approach to tackle global biodiversity decline. , The harvest ... world,s people and provides protein for more than a ... no surprise that today,s unprecedented loss of wildlife, is ...
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... effects on different species of fish, according to ... and Exeter which tested fish anti-predator behaviour. ... seagull predator model when exposed to additional noise, ... , Lead author Dr Irene Voellmy of ... in many aquatic environments have increased substantially during ...
Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... In the May 15th issue of G&D, Dr. Michael Carey ... into the mechanism of epigenetic silencing of euchromatic genes. ... direction to understand how histone and DNA methylation, two phenomena ... cancer, can communicate with each other to turn genes off. ...
... a mystery why the speed and complexity of evolution appear ... that single-celled life first appeared about 3.5 billion years ago, ... multi-cellular life to evolve. That leaves just a billion years ... plants, mammals, insects, birds and other species that populate the ...
... have developed an inexpensive, nonchlorine-based technology that can ... , UD's patented technology, developed jointly by ... Resources and the College of Engineering, incorporates highly ... a chemical "knock-out punch" to a host of ...
Cached Biology News:Does evolution select for faster evolvers? 2New UD technology removes viruses from drinking water 2New UD technology removes viruses from drinking water 3New UD technology removes viruses from drinking water 4
...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
Integrins Sampler Kit 10g each...
Biology Products: